These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35528817)

  • 21. TLP01, an mshA mutant of Vibrio cholerae O139 as vaccine candidate against cholera.
    Ledón T; Ferrán B; Pérez C; Suzarte E; Vichi J; Marrero K; Oliva R; Fando R
    Microbes Infect; 2012 Sep; 14(11):968-78. PubMed ID: 22546527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The state-of-the-art of approved and under-development cholera vaccines.
    Pastor M; Pedraz JL; Esquisabel A
    Vaccine; 2013 Aug; 31(38):4069-78. PubMed ID: 23845813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of a detection system for wild-type Vibrio cholerae in genetically modified cholera vaccine.
    Studer E; Candrian U
    Biologicals; 2000 Sep; 28(3):149-54. PubMed ID: 10964441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine.
    Adekunle O; Dretler A; Kauffman RC; Cho A; Rouphael N; Wrammert J
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009743. PubMed ID: 34478460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A polyvalent multiepitope protein cross-protects against
    Upadhyay I; Li S; Ptacek G; Seo H; Sack DA; Zhang W
    Proc Natl Acad Sci U S A; 2022 Dec; 119(50):e2202938119. PubMed ID: 36469767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.
    Vishwakarma V; Sahoo SS; Das S; Ray S; Hardt WD; Suar M
    Vaccine; 2015 Apr; 33(15):1880-9. PubMed ID: 25701672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular analysis of rRNA and cholera toxin genes carried by the new epidemic strain of toxigenic Vibrio cholerae O139 synonym Bengal.
    Faruque SM; Abdul Alim AR; Roy SK; Khan F; Nair GB; Sack RB; Albert MJ
    J Clin Microbiol; 1994 Apr; 32(4):1050-3. PubMed ID: 7517950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR.
    Kaper JB; Michalski J; Ketley JM; Levine MM
    Infect Immun; 1994 Apr; 62(4):1480-3. PubMed ID: 8132356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
    Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
    Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular analysis of toxigenic Vibrio cholerae O139 Bengal strains isolated in Bangladesh between 1993 and 1996: evidence for emergence of a new clone of the Bengal vibrios.
    Faruque SM; Ahmed KM; Siddique AK; Zaman K; Alim AR; Albert MJ
    J Clin Microbiol; 1997 Sep; 35(9):2299-306. PubMed ID: 9276406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and assessment of its reactogenicity and immunogenicity in the rabbit model.
    Thungapathra M; Sharma C; Gupta N; Ghosh RK; Mukhopadhyay A; Koley H; Nair GB; Ghosh A
    Immunol Lett; 1999 Jun; 68(2-3):219-27. PubMed ID: 10424424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral vaccines against cholera: lessons from Vietnam and elsewhere.
    Levine MM
    Lancet; 1997 Jan; 349(9047):220-1. PubMed ID: 9014902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vibrio cholerae cytolysin is essential for high enterotoxicity and apoptosis induction produced by a cholera toxin gene-negative V. cholerae non-O1, non-O139 strain.
    Saka HA; Bidinost C; Sola C; Carranza P; Collino C; Ortiz S; Echenique JR; Bocco JL
    Microb Pathog; 2008 Feb; 44(2):118-28. PubMed ID: 17919878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
    Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Song KR; Chapagain RH; Tamrakar D; Shrestha R; Kanodia P; Chaudhary S; Wartel TA; Yang JS; Kim DR; Lee J; Park EL; Cho H; Lee J; Thaisrivichai P; Vemula S; Kim BM; Gupta B; Saluja T; Pansuriya RK; Ganapathy R; Baik YO; Lee YJ; Jeon S; Park Y; Her HL; Park Y; Lynch JA
    Lancet Glob Health; 2024 May; 12(5):e826-e837. PubMed ID: 38614631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.